Low SHBG emerges as a telltale marker of PCOS

Sex hormone-binding globulin is a glycoprotein that regulates how much of your sex steroid hormones circulate in a bioavailable form, and interest in it has escalated because low levels are inversely associated with polycystic ovary syndrome, obesity, insulin resistance, metabolic syndrome and type 2 diabetes. PCOS itself is diagnosed through a mix of criteria, and a reliable blood biomarker would be valuable for both prediction and monitoring. This meta-analysis set out to establish how strongly SHBG is associated with PCOS, how it correlates with the endocrine and metabolic dysregulation that accompanies the condition, and whether treatment changes it: in short, whether SHBG deserves a place as a PCOS biomarker.

The authors ran a systematic literature search across PubMed, ScienceDirect, Google Scholar, EMBASE and the Cochrane Library, registered on PROSPERO. From 675 relevant records identified, 62 articles met the criteria for inclusion. Meta-analysis was performed using a random-effects model to calculate standardised mean differences with 95% confidence intervals, comparing serum SHBG levels between women with PCOS and controls. The review also examined how SHBG correlated with PCOS-associated endocrine and metabolic dysregulation, and assessed the effects of various therapeutic agents on SHBG levels in women with the condition.

SHBG levels in controls were significantly higher than in women with PCOS, with a pooled standardised mean difference of -0.83 (95% CI -1.01 to -0.64): a clear and statistically robust gap. Heterogeneity across studies was significant and very high (I2 of 93.9%), meaning individual studies varied considerably in the size of the difference they found. Beyond the headline comparison, the results suggest SHBG plays a role in the various metabolic disturbances seen in PCOS. Therapeutic interventions improved SHBG levels in women with PCOS, and this improvement was linked to a reduction in PCOS-associated complications.

This synthesis consolidates a long-suspected relationship into pooled evidence across 62 studies, supporting the idea that low SHBG is a consistent feature of PCOS rather than a quirk of individual cohorts. It fits a wider literature tying low SHBG to obesity, insulin resistance, metabolic syndrome and type 2 diabetes, positioning the protein at the crossroads of hormonal and metabolic health. What it does not settle is causality, whether low SHBG helps drive PCOS biology or simply reflects it, nor does it define diagnostic cut-off values. The very high heterogeneity also signals that assay methods and populations differed widely, an issue future standardised studies would need to resolve.

SHBG appears on many standard hormone blood panels, so this is useful context for reading your own results: consistently low SHBG is one of the signals associated with PCOS and with broader metabolic disturbance, which is a reason to discuss an unexpected result with a clinician rather than ignore it. It is equally a reason not to over-read a single number: the association is strong at the group level, but SHBG alone cannot diagnose PCOS, and levels shifted with treatment in these studies, showing the marker is not fixed. Think of it as one informative piece of a larger hormonal and metabolic picture.